TY - JOUR
T1 - Weekly carboplatin in a frail elderly woman with advanced peritoneal carcinoma.
AU - Piura, Benjamin
AU - Meirovitz, Mihai
PY - 2005/1/1
Y1 - 2005/1/1
N2 - INTRODUCTION: Standard chemotherapy for ovarian, peritoneal and fallopian tube carcinoma has been a combination of carboplatin (AUC = 6) and paclitaxel 175 mg/m2 every 3 weeks. For frail and elderly patients who may not tolerate the toxicity associated with combination chemotherapy there is the option of omitting paclitaxel and giving carboplatin (AUC = 6) as a single agent every 3 weeks. The toxicity may be reduced further, without decreasing effectiveness, by giving single-agent carboplatin at a reduced dose (AUC = 2) every week. CASE REPORT: A frail 79-year-old woman with advanced peritoneal carcinoma had first-line and second-line chemotherapy with single-agent carboplatin on day 1 every 7 days. This has resulted in disease stabilization, CA-125 partial response and improved quality of life. Toxicity has been negligible. CONCLUSION: Weekly carboplatin is an attractive option for the treatment of frail and elderly patients with ovarian, peritoneal and fallopian tube carcinoma.
AB - INTRODUCTION: Standard chemotherapy for ovarian, peritoneal and fallopian tube carcinoma has been a combination of carboplatin (AUC = 6) and paclitaxel 175 mg/m2 every 3 weeks. For frail and elderly patients who may not tolerate the toxicity associated with combination chemotherapy there is the option of omitting paclitaxel and giving carboplatin (AUC = 6) as a single agent every 3 weeks. The toxicity may be reduced further, without decreasing effectiveness, by giving single-agent carboplatin at a reduced dose (AUC = 2) every week. CASE REPORT: A frail 79-year-old woman with advanced peritoneal carcinoma had first-line and second-line chemotherapy with single-agent carboplatin on day 1 every 7 days. This has resulted in disease stabilization, CA-125 partial response and improved quality of life. Toxicity has been negligible. CONCLUSION: Weekly carboplatin is an attractive option for the treatment of frail and elderly patients with ovarian, peritoneal and fallopian tube carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=33747851502&partnerID=8YFLogxK
U2 - 10.1007/s00404-005-0024-z
DO - 10.1007/s00404-005-0024-z
M3 - Article
AN - SCOPUS:33747851502
SN - 0932-0067
VL - 273
SP - 192
EP - 194
JO - Archives of Gynecology and Obstetrics
JF - Archives of Gynecology and Obstetrics
IS - 3
ER -
